PDF) Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Phase II trials of metronomic temozolomide schedules for glioblastoma | Download Table
Cancers | Free Full-Text | Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells
Phase II trials of metronomic temozolomide schedules for glioblastoma | Download Table
PDF) Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Biomedicines | Free Full-Text | Considering the Experimental Use of Temozolomide in Glioblastoma Research
Preliminary results from the NCT02770378 proof-of-concept clinical trial assessing the safety of the Coordinated Undermining of
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis
PDF) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours | Darren Hargrave and Albert Moghrabi - Academia.edu
Enhanced Copper–Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme | ACS Applied Materials & Interfaces
Current Treatment Options for the Management of Glioblastoma Multiforme
Hydrolytic instability and low-loading levels of temozolomide to magnetic PLGA nanoparticles remain challenging against glioblastoma therapy - ScienceDirect
Treatment of Glioblastoma | JCO Oncology Practice
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity | springermedizin.de
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2 - ScienceDirect
Frontiers | Temozolomide – Just a Radiosensitizer?
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images - Wu - 2020 - NMR in Biomedicine - Wiley Online Library
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions | PLOS ONE
